DrugRisk Adds Latest Updates for Pradaxa Bleeding Lawsuits


The DrugRisk Resource Center is the Web's largest source for information on drug and medical device warnings, side effects and legal news. Visit http://www.DrugRisk.com

Orlando, FL (PRWEB) January 01, 2013

The prescription drug resource center DrugRisk.com is announcing the addition of new information to its already comprehensive database for the blood thinner Pradaxa, after a federal court handling injury claims scheduled the next conference and the start of trials.

“DrugRisk's goal is to improve consumer safety through education of the latest drug warnings, recalls, studies and litigation news. Therefore, we felt it important that patients know the latest updates in the ongoing lawsuits over alleged internal bleeding from Pradaxa,” explained DrugRisk representative Ryan Mayer.

The resource center had previously advised that the number of patients filing a Pradaxa lawsuit claiming internal bleeding has risen 50% since September.* The cases have now been moved to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Now, Judge David Herndon, who is overseeing the Pradaxa litigation, has scheduled the next conference for January 14th and the first trial for August 2014, according to Case Management Order Number 11, Judge David Herndon (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

DrugRisk recently announced a warning by the U.S. FDA on December 19th, that patients with mechanical heart valves may face a greater risk of strokes, heart attacks, or blood clots from Pradaxa than with warfarin after results from clinical trials in Europe.**

The Drug Risk center also cautions that experts disagree about the safety of Pradaxa and the risk for bleeding. Last month the FDA updated warnings to say the drug carries the same risks as warfarin.*** However, the New York Times also reported doctors' concerns that Pradaxa led all medications for adverse reports and currently has no antidote for internal bleeding.****

Most common among the adverse reports were 6497 gastrointestinal side effects, 4910 gastrointestinal hemorrhages (bleeding) and 2941 central nervous system or cranial hemorrhaging problems. There were also 842 deaths attributed to the drug.

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.


For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-lawsuits/pradaxa-litigation/prweb10282904.htm